نمایش پرونده ساده آیتم

dc.contributor.authorHashemilar, M
dc.contributor.authorBarzegar, M
dc.contributor.authorNikanfar, M
dc.contributor.authorBonyadi, MR
dc.contributor.authorGoldust, M
dc.contributor.authorRamouz, A
dc.contributor.authorEbrahimi, F
dc.date.accessioned2018-08-26T08:54:14Z
dc.date.available2018-08-26T08:54:14Z
dc.date.issued2013
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54101
dc.description.abstractObjective: Antiganglioside antibodies have been reported to play a role in the pathophysiology of Guillain-Barrأ© syndrome (GBS). Methods: This case-control study was designed to evaluate the status of antiganglioside antibodies in children with GBS. The study included 50 patients suffering from GBS as the case group and 30 children as the control group. Clinical information such as demographic data and recent digestive or respiratory infection (within the last month) was collected for all patients, and paraclinical studies including cerebrospinal fluid examination and electrophysiology were conducted by a subspecialized physician. Anti-GM1, anti-GQ1 and anti-GD1a antibodies were measured with ELISA and the EUROLINE method. Results: The mean age of patients in the case and control groups was 5.3 آ± 3.8 and 5.4 آ± 3.4 years, respectively. With the EUROLINE method, the results obtained for anti-GM1 were significant (p = 0.007); however, the p values for anti-GQ1a and anti-GQ1b were not significant (0.051 vs. 0.94), while with ELISA, comparing all three antibodies in both the case and control groups showed statistically significant results, with a p < 0.05. Conclusion: EUROLINE is a new method used to evaluate antibodies in immune system diseases, but it is not useful for all antibodies specific to GBS, as the analysis was significant with a p value of 0.007 for anti-GM2. آ© 2013 S. Karger AG, Basel.
dc.language.isoEnglish
dc.relation.ispartofNeuroImmunoModulation
dc.subjectganglioside antibody
dc.subjectganglioside GD1a antibody
dc.subjectganglioside GM1 antibody
dc.subjectganglioside GQ1 antibody
dc.subjectunclassified drug
dc.subjectganglioside GD1b antibody
dc.subjectarticle
dc.subjectblood sampling
dc.subjectcase control study
dc.subjectcerebrospinal fluid examination
dc.subjectchild
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdemography
dc.subjectelectrophysiology
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectgastrointestinal infection
dc.subjectGuillain Barre syndrome
dc.subjecthuman
dc.subjectimmunopathogenesis
dc.subjectmale
dc.subjectpathophysiology
dc.subjectphysician
dc.subjectpreschool child
dc.subjectpriority journal
dc.subjectrespiratory tract infection
dc.subjectschool child
dc.subjectantibody blood level
dc.subjectantibody detection
dc.subjectArticle
dc.subjectchildhood disease
dc.subjectcontrolled clinical trial
dc.subjectenzyme linked immunosorbent assay
dc.subjectEUROLINE method
dc.subjectGuillain Barre syndrome
dc.subjectintermethod comparison
dc.subjectpredictive value
dc.subjectsensitivity and specificity
dc.subjectWestern blotting
dc.subjectAntibodies
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFemale
dc.subjectGangliosides
dc.subjectGuillain-Barre Syndrome
dc.subjectHumans
dc.subjectMale
dc.subjectRetrospective Studies
dc.subjectSensitivity and Specificity
dc.titleEvaluating the status of antiganglioside antibodies in children with Guillain-Barrأ© syndrome
dc.typeArticle
dc.citation.volume21
dc.citation.issue1
dc.citation.spage64
dc.citation.epage68
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1159/000355830


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم